Table 4.
Awareness of and views on evidence about androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT) by country
| Survey respondents, n (%) |
||||
|---|---|---|---|---|
| Canada | UK | Other | Total | |
| Awareness of trial results | ||||
| Aware of PR.3/PR07 results? | ||||
| Yes, read Lancet paper | 60 (81) | 82 (80) | 8 (100) | 150 (81) |
| Yes, other source | 12 (16) | 19 (18) | 0 | 31 (17) |
| No | 2 (3) | 2 (2) | 0 | 4 (2) |
| Aware of SPCG7/SFUO3 results | ||||
| Yes, read Lancet paper | 42 (58) | 59 (58) | 6 (86) | 107 (59) |
| Yes, other source | 13 (18) | 21 (21) | 1 (14) | 35 (19) |
| No | 18 (25) | 22 (22) | 0 | 40 (22) |
| Have the results of these trials influenced your clinical practice? | ||||
| Already generally using ADT + EBRT | 58 (77) | 56 (56) | 6 (75) | 120 (66) |
| Now generally use ADT + EBRT | 16 (21) | 44 (44) | 2 (25) | 62 (34) |
| Not generally using ADT + EBRT | 1 (1) | 0 | 0 | 1 (1) |
| Is the evidence strong enough for ADT + EBRT to be the standard of care for men with locally advanced prostate cancer? | ||||
| Yes | 68 (91) | 89 (88) | 6 (75) | 163 (89) |
| No | 4 (5) | 4 (4) | 1 (13) | 9 (5) |
| Not sure | 3 (4) | 8 (8) | 1 (13) | 12 (7) |